These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30181782)

  • 1. Activation of viral defense signaling in cancer.
    Gonzalez-Cao M; Karachaliou N; Santarpia M; Viteri S; Meyerhans A; Rosell R
    Ther Adv Med Oncol; 2018; 10():1758835918793105. PubMed ID: 30181782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleotide oligomerization and binding domain 2-dependent dendritic cell activation is necessary for innate immunity and optimal CD8+ T Cell responses to influenza A virus infection.
    Lupfer C; Thomas PG; Kanneganti TD
    J Virol; 2014 Aug; 88(16):8946-55. PubMed ID: 24872587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting STING for cancer immunotherapy: From mechanisms to translation.
    Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemplating the Importance of Toll-like Receptors I and II Regarding Human Viral Pathogenesis.
    Saeed U; Mazoor S; Jalal N; Zahid Piracha Z
    Jundishapur J Microbiol; 2015 Jan; 8(1):e13348. PubMed ID: 25763131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy.
    Hoden B; DeRubeis D; Martinez-Moczygemba M; Ramos KS; Zhang D
    Front Immunol; 2022; 13():1033483. PubMed ID: 36389785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer.
    Rolfo C; Giovannetti E; Martinez P; McCue S; Naing A
    NPJ Precis Oncol; 2023 Mar; 7(1):26. PubMed ID: 36890302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-Like Receptors in Adaptive Immunity.
    Kumar V
    Handb Exp Pharmacol; 2022; 276():95-131. PubMed ID: 34510306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate and adaptive immune responses in HCV infections.
    Heim MH; Thimme R
    J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases.
    Zhang E; Ma Z; Lu M
    Cell Mol Life Sci; 2022 Oct; 79(11):547. PubMed ID: 36224474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles for Innate Immunity in Combination Immunotherapies.
    Moynihan KD; Irvine DJ
    Cancer Res; 2017 Oct; 77(19):5215-5221. PubMed ID: 28928130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Just eat it: A review of CD47 and SIRP-α antagonism.
    Oronsky B; Carter C; Reid T; Brinkhaus F; Knox SJ
    Semin Oncol; 2020; 47(2-3):117-124. PubMed ID: 32517874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting innate immunity for cancer immunotherapy.
    Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
    Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
    Goldberg JL; Sondel PM
    Semin Oncol; 2015 Aug; 42(4):562-72. PubMed ID: 26320061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate and Adaptive Immune Responses in Wound Epithelialization.
    Strbo N; Yin N; Stojadinovic O
    Adv Wound Care (New Rochelle); 2014 Jul; 3(7):492-501. PubMed ID: 25032069
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antiinfective host defense mechanism: toll-like receptors and innate immunity].
    Takesue Y; Ohge H; Kohyama M; Imamura Y; Murakami Y; Sueda T
    Nihon Geka Gakkai Zasshi; 2003 Jul; 104(7):494-8. PubMed ID: 12884772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment.
    Storey KM; Lawler SE; Jackson TL
    Front Physiol; 2020; 11():151. PubMed ID: 32194436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.